Vistagen Therapeutics Inc (VTGN) Wows Investors with a New Patent Victory
It’s a very rewarding trading day for investors in Vistagen Therapeutics Inc (NASDAQ:VTGN) with shares rising over 140%, making the stock Wall Street’s bull of the day. The reason? The tiny drug maker announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent which covers the use of certain methods of production for AV-101, VistaGen’s oral CNS drug candidate in Phase 2 development for major depressive disorder (MDD).
VistaGen CEO Shawn Singh opined, “The issuance of this U.S. patent by the USPTO advances our intellectual property strategy for AV-101 at this vital period in its clinical development. This issued U.S. patent, in conjunction with the potential issuance of additional AV-101 patent applications currently under review worldwide, provides VistaGen with added long-term intellectual property protection for AV-101 and enhances its commercial potential.”
Similarly, last month, the European Patent Office (EPO) granted a European Patent for AV-101. The patent relates to the treatment of depression, Parkinson’s disease levodopa-induced dyskinesia (PD LID) and use of multiple dosage forms to treat these CNS disorders. The patent has been validated in Belgium, Denmark, France, Germany, Ireland, Italy, Portugal, Spain, Switzerland and the United Kingdom. It will be in effect until January 2034.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system. Its product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 development, initially for the adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to standard antidepressants.